Pegcetacoplan: Advancing the First Potential Treatment for Geographic Atrophy (GA) Presentation

Pegcetacoplan: Advancing the First Potential Treatment for Geographic Atrophy (GA)

Virtual Investor Event

January 28, 2021

Forward-looking Statements

Statements in this presentation about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the implications of preliminary clinical data. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward- looking statements as a result of various important factors, including: whether the company's clinical trials will be fully enrolled and completed when anticipated; whether preliminary or interim results from a clinical trial will be predictive of the final results of the trial; whether results obtained in preclinical studies and clinical trials

will be indicative of results that will be generated in future clinical trials; whether pegcetacoplan will successfully advance through the clinical trial process on a timely basis, or at all; whether the results of the company's clinical trials will warrant regulatory submissions and whether pegcetacoplan will receive approval from the FDA or equivalent foreign regulatory agencies for GA, PNH, CAD, HSCT- TMA, C3G, IC-MPGN, ALS or any other indication when expected or at all; whether, if Apellis' products receive approval, they will be successfully distributed and marketed; and other factors discussed in the "Risk Factors" section of Apellis' Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 2, 2020 and the risks described in other filings that Apellis may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

2

FOR APELLIS USE ONLY

Disclosures

C A R O L I N E R . B A U M A L	Consultant: Apellis, Genentech, Novartis, Gemini Therapeutics, Zeiss
	Consultant: Allergan, Acucela, Apellis, Bayer, Lineage Cell Therapeutics, Clearside Biosciences,
	Gemini, Genentech, Gyroscope, Katalyst Surgical, Nacuity, Notal Vision, Novartis, Polyactiva,
N A N C Y M . H O L E K A M P	Regeneron
• Speakers Bureau: Allergan, Genentech, Novartis, Regeneron, Spark
	• Contracted Research: Genentech, Gemini, Gyroscope, Notal Vision
	• Intellectual Property/Patent: Katalyst Surgical
	Consultant: 4DMT, Adverum, Aerie, Aerpio, Aldeyra, Allegro, Alzheon, Annexon, Apellis, Aprea,
	Asclepix, Aviceda, BVT, Dark Horse, DTx, Eloxx, Galimedix, Genentech, Graybug, Gyroscope,
J E F F R E Y S . H E I E R	Iveric, jCyte, Kanghong, LensGen, NGM, Novartis, Ocular Therapeutix, OcuTerra, Oxurion, Palatin,
Regeneron, Regenxbio, Stealth, Thea, Verseon, Vinci, Voyant
	Research: Apellis, Asclepix, Bayer, Genentech, Graybug, Gyroscope, Hemera, Iveric, Kanghong,
	Kodiak, NGM, Notal Vision, Novartis, Regeneron, Regenxbio, Stealth
P E A R S E A . K E A N E	Consultant: DeepMind, Roche, Novartis, and Apellis. Dr. Keane is an equity owner in Big Picture
Medical and has received speaker fees from Heidelberg Engineering, Topcon, Allergan, and Bayer.

3

FOR APELLIS USE ONLY

Agenda

Introductions	F E D E R I C O G R O S S I , M . D . , P H . D		C E D R I C F R A N C O I S , M . D . , P H . D .
Chief Medical Officer, Apellis		Chief Executive Officer, Apellis
Overview of Age-related Macular	C A R O L I N E R . B A U M A L , M . D .
Professor of Ophthalmology
Degeneration (AMD)
Tufts Medical Center, New England Eye Center, Retina Department
	N A N C Y M . H O L E K A M P, M . D .
Natural History and Unmet Need in GA	Director, Retina Services
	Pepose Vision Institute
Role of Complement C3 in AMD	L U K A S S C H E I B L E R , P H . D .
Chief Innovation Officer, Apellis
	J E F F R E Y S . H E I E R , M . D .
Pegcetacoplan: Phase 2 FILLY Results	Director, Retina Service and Director, Retinal Research
	Ophthalmic Consultants of Boston
Pegcetacoplan: Phase 3 DERBY and	J E F F R E Y E I S E L E , P H . D .
OAKS Studies	Local Chronic Program Lead, Apellis
Early Detection of Geographic Atrophy	P E A R S E A . K E A N E , M . D .
Consultant Ophthalmologist, Moorfields Eye Hospital NHS Foundation Trust
with Artificial Intelligence
Associate Professor, University College London
Q&A	A L L

4